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Abstract
Without treatment, Cushing’s disease has significant morbidity and mortality. Where a surgical approach may not be feasible, or is refused 
by the patient, medical therapy becomes the only option. In this case report, we discuss the effects of two years of ketoconazole treatment 
on diabetes regulation and insulin resistance in a patient reluctant to agree to surgery. A 62 year-old female patient with uncontrolled type 
2 diabetes mellitus was investigated. Cushing’s disease was confirmed by the results of high urine free cortisol level and dexamethasone 
suppression tests.
We discuss the effects of two years of 600 mg/day ketoconazole treatment on diabetes regulation and insulin resistance in a patient with 
Cushing’s disease reluctant to agree to surgery. This case report illustrates the beneficial long-term effects of 24 months of ketoconazole 
treatment on the clinical and laboratory findings and also on steroid and glucose metabolism. (Pol J Endocrinol 2011; 62 (3): 271–274)
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Introduction
Cushing’s disease has great morbidity and mortality if 
not treated properly. Usually, cardiovascular complica-
tions which occur as a result of metabolic disorders are 
responsible for this high morbidity and mortality [1]. 
Insulin resistance due to hypercortisolemia decreases 
utilisation of glucose at peripheral tissues, and dis-
turbed glucose tolerance (30–60%) and overt diabetes 
mellitus (25–50%) consequently occur [2, 3]. Insulin 
resistance may reflect impaired insulin-dependent 
down-regulation of hepatic glucose release and/or im-
paired insulin-mediated increase in peripheral glucose 
uptake. Cortisol can activate either glucocorticoid (type 
2 corticosteroid) or mineralocorticoid (type 1 corticos-
teroid) receptors, although it has a greater affinity for 
the latter [4–6]. 
Cushing’s disease creates insulin resistance by af-
fecting at postreceptor level. Surgical intervention is 
the treatment of choice when the etiology is found. 
If a surgical approach is not applicable, or is refused 
by the patient, medical therapy becomes the only op-
tion. Steroidogenesis inhibitors such as ketoconazole, 
metyrapone, mitotane and aminoglutethimide are 
among the choices for medical therapy. But currently 
no medical agent can be accepted as the optimal choice 
of therapy [7].
We discuss here the positive effects of two years 
of ketoconazole treatment on steroid and glucose me-
tabolism and homeostatic model assessment (HOMA) 
in a 62 year-old female patient being followed up with 
a diagnosis of Cushing’s disease and unregulated dia-
betes mellitus.
Case report
A 62 year-old female patient with type 2 diabetes mel-
litus who was followed up in another clinic, attended 
our clinic with unregulated glycaemic control. She had 
been treated for hypertension and hyperlipidemia for 
15 years and eight years respectively. She had previ-
ously undergone coronary artery bypass surgery. Her 
daily treatment consisted of 10 mg amlodipine, 5 mg 
ramipril, 90 mg diltiazem, 50 mg aldactazide, 20 mg 
atorvastatin, 100 mg aspirin, 30 units of regular insulin 
and 10 units of NPH insulin. There was no cigaratte 
or alcohol consumption. Her body mass index was 
31 kg/m2 and she had truncal obesity. Blood pressure 
was 150/100 mmHg and heart rate was 62 min/rhyth-
mic. Lower extremity oedema was found bilaterally. 
Proximal muscle weakness (3/5) was revealed. Other 
than a 2/6 systolic murmur at the 5th mid-clavicular 
intercostal space, she had normal physiological 
findings. Haemogram tests were normal. Normal 
Ketoconazole treatment in diabetic Cushing’s disease Meral Mert, Gonenc Kocabay
272
O
PI
SY
 P
R
Z
Y
PA
D
K
Ó
W
ejection fraction and moderate mitral insufficiency 
were found in echocardiographic investigation. The 
biochemical examination of blood was as follows: glu-
cose 320 mg/dl, BUN 83 mg/dL, creatinine 1.7 mg/dl, 
sodium 138 mmol/l, potassium 4 mmol/l, total cho-
lesterol 122 mg/dl, LDL-cholesterol 75 mg/dl (under 
statin therapy), HDL-cholesterol 30 mg/dl, triglyceride 
125 mg/dl, C-peptide 1.2 ng/ml. Thyroid function tests 
and thyroid autoantibody levels were normal. HbA1c 
was 11.9%. Proteinuria of 120 μ/day and 40 ml/min 
clearance of creatinine were detected. Preprolifera-
tive retinopathy was found. Following hospitalisa-
tion, blood glucose levels were measured five times 
a day. Instead of oral anti-diabetic therapy, intensive 
insulin treatment was given because of chronic renal 
insufficiency. The average insulin dose was 220 units 
per day. Despite adequate insulin treatment (2 units 
per kg), blood glucose could not be regulated. To pre-
vent glucotoxicity, insulin treatment was conducted 
as 48 hours of infusion. We planned an appropriate 
dietary programme. 
No further pathology was found except pangastri-
tis in endoscopic evaluation. Abdominal ultrasonog-
raphy showed grade 2 hepatosteatosis and a left ad-
renal adenoma of 2 × 3 cm, which was also confirmed 
by magnetic resonance imaging (MRI). The mass was 
found hypointense on T1-weighted sequences and 
hyperintense in T2 sequences, which is significant for 
adenoma by MRI (Figure 1). To determine the function 
of the mass, several hormone tests were conducted, 
the results of which were as follows: serum aldoster-
one (ng/dl)/plasma activity of renin (ng/ml/h) ratio 1.5, 
vanil mandelic acid 2.3 mg/day (n: 1–11 mg/day), no-
radrenaline 32 μg/day (n: 23–105 μg/day), adrenaline 
5.7 μg/day (n: 4–20 μg/day), dopamine 146 mg/day (n: 
190–450 mg/day), normetanephrine 278 μg/day (n: 
105–354 μg/day), metanephrine 291 μg/day (n: 74–297 
μg/day). These results were found from the 24 hour 
urine examination.
ACTH-dependent Cushing’s disease was confirmed 
by the result of high urine free cortisol level and serum 
cortisol levels unsuppressed by low dose (> 1.8 μg/dl) 
and suppressed by high dose dexamethasone tests (Ta-
ble I). Both changes of urinary free cortisol and serum 
cortisol after low dose and high dose dexamethasone 
suppression tests before and after ketoconazole therapy 
are shown in Table I. An 8 × 7 mm diameter micro-
adenoma showing heterogenous enhancement with 
contrast was detected posteriorly on the pituitary MRI 
examination (Figure 2).
Surgical mass extraction was proposed, which was 
refused by the patient. So,  ketoconazole treatment 
600 mg/day was given to prevent steroid synthesis. Body 
mass index did not change, however total insulin re-
quirements decreased to 55% and the needs of insulin 
per kg decreased from 2.0 units/kg to 1.2 units/kg dur-
ing the ketoconazole 600 mg/day treatment which was 
continued for two years. Afterwards, the HbA1c value 
was 8.2%. Since the patient had been using insulin, HO-
MA-IR was calculated by C-peptide levels. HOMA-IR 
Figure 1. Magnetic resonance imagine. The mass was found hypointense on T1-weighted sequences and hyperintens in T2 sequences
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levels had decreased from 3.2 to 1.1 at the end of the two 
years [8]. The results of plasma cortisol after overnight 
dexamethasone test and urinary free cortisol value were 
detected as 1.78 μg/dl and 50 μg/dl respectively at the 
end of the two year treatment. There was a significant 
improvement in the constitutional complaints. Muscle 
strength was improved. No change in the mass size was 
detected in the MRI. The same treatment is still being 
conducted today.
Discussion
Ketoconazole is a wide spectrum antifungal agent 
that inhibits adrenal and testicular steroids reversibly. 
Several studies havereported that ketoconazole treat-
ment results in 30–90% remission in Cushing’s disease, 
with even higher rates being obtained in Cushing’s 
syndrome of adrenal origin. 
But what the duration and dose of therapy should 
be is yet to be established. Literature reports patients 
who have been administered ketoconazole for between 
15 days and 13 years at various doses [9]. Sanino et al. 
[10] treated five female patients with Cushing’s disease 
with ketoconazole for one month at 800 mg/day and 
for two months at 600 mg/day, and they observed 
significant clinical and laboratory improvements in 
all patients. 
Angeli et al. [11] detected a rapid improvement 
in five female patients with hypophyseal Cushing’s 
disease during the first two weeks of ketoconazole 
therapy. This improvement became more prominent 
in 1–2 months and was highest at the third month of 
therapy. Kong et al. [12] treated patients with Cush-
ing’s syndrome of adrenal origin for one month with 
500 mg/day aminoglutethimide and with 600 mg/day 
ketoconazale during the following six weeks and then 
followed the patients for nine months with 400 mg/day 
ketoconazole. They reported that with ketoconazole 
treatment improvement in laboratory and clinical 
settings is obtained at a dose of 0.6 mg/day. HOMA is 
a parameter used in detecting beta cell function and 
insulin resistance. It is calculated from fasting blood 
glucose and insulin levels or C-peptide concentration. 
Since it was first described in 1985, computer models 
have been used instead of mathematical formulas and 
these models have been validated in many studies. [13]
Table 1. Tests for Cushing’s syndrome
Basal 
cortisol  
[μg/dl]
Urinaryfree 
cortisol  
[μg/dl]
Over  
night  
DST
Low  
dose  
DST
High  
dose  
DST
ACTH  
[pg/ml] 
(n: < 50)
17-aOH 
progesterone 
[ng/ml] 
(n: 0.23–1.36)
DHEAS  
[μg/dl] 
(n: 38–313)
Testosterone  
[ng/ml] 
(n: 1.8–7.8)
Initial results 
at diagnosis
15.6 190 4.72 10.25 2.97 25 0.8 35 0.5
Results after 
second year of 
treatment
14 50 1.78
DST — dexamethasone suppression test
Figure 2. 8 × 7 mm daimeter microadenoma showing heterogenous enhancement with contrast was detected posteriorly on the pituitary 
MRI examination
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In our case, we proposed surgical intervention to the 
patient. Because the patient refused the surgery, we gave 
ketoconazole at 600 mg/day. There is no very strong proof 
regarding this therapy modality in the literature. The 
clinical and laboratory findings in our case decreased. 
A significant improvement in the constitutional com-
plaints was revealed, and muscle strength improved. 
The results of plasma cortisol after overnight dex-
amethasone test and urinary free cortisol value were 
detected as 1.78 μg/dl and 50 μg/dl respectively at the 
end of the second year. Declines in the insulin (55%) 
and A1c levels (–3.7%) were found after two years of 
treatment. The glycaemic regulation was improved 
by reduction of insulin resistance. Since the patient 
had been using insulin, HOMA-IR was calculated by 
C-peptide levels. HOMA-IR levels decreased from 
3.2 to 1.1 at the end of the two years, a decline of two 
thirds. Metformin could not be used because of renal 
insufficiency. According to this, the cause of the reduc-
tion in insulin resistance was thought to be due to the in-
hibition of steroid synthesis. Despite reports of adverse 
affects of ketoconazole treatment such as hepatic failure 
(12%) [14–16] and hypoadrenalism and gastrointestinal 
complaints, no adverse effect was seen in our patient.
In conclusion, this case report supports the beneficial 
long-term effects of 24 months of ketoconazole treat-
ment on the clinical and laboratory findings and also 
on steroid and glucose metabolism.
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